Meeting
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
Authors
Jian Li Campian
Mayo Clinic in Rochester, Rochester, MN
Jian Li Campian , Omar H. Butt , Jiayi Huang , Jingqin Luo , Yu Tao , Roy E. Strowd , Deanna C Hissim , Sani Haider Kizilbash , Christopher Abraham , George Ansstas , Tanner Michael Johanns , Albert H. Kim , Matthew A. Ciorba , Milan G Chheda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03532295
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2058)
DOI
10.1200/JCO.2022.40.16_suppl.2058
Abstract #
2058
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.
First Author: Jian Li Campian
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah
Poster
2018 ASCO Annual Meeting
Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.
First Author: Lakshmi Nayak